Cisplatin-based (PVB+M) chemotherapy in good-risk and poor-risk nonseminomatous germ cell tumors
| Autor: | Gopal Ramakrishnan, Tapan K. Saikia, Hedge U, Prafulla B. Desai, Jagdeesh N. Kulkarni, Suresh H. Advani |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Male
medicine.medical_specialty Time Factors medicine.medical_treatment Urology Vinblastine Bleomycin Metastasis chemistry.chemical_compound Testicular Neoplasms Risk Factors Antineoplastic Combined Chemotherapy Protocols medicine Humans Cisplatin Chemotherapy Poor risk business.industry General Medicine Neoplasms Germ Cell and Embryonal medicine.disease Surgery Survival Rate Methotrexate Oncology chemistry Germ cell tumors business Follow-Up Studies medicine.drug |
| Zdroj: | Journal of Surgical Oncology. 51:100-103 |
| ISSN: | 1096-9098 0022-4790 |
| DOI: | 10.1002/jso.2930510207 |
| Popis: | Twenty-seven patients with metastatic nonseminomatous germ cell tumors were treated with Cisplatin, vinblastine, bleomycin, and low-dose meth-otrexate (PVB + M) combinations. Patients were divided into good-risk and poor-risk groups. All seven patients (100%) with good-risk factors achieved complete response, and all are alive disease free at a median of 70 months. In the poor-risk group, only 10 of 20 patients (50%) achieved complete response, and seven (35%) are alive disease free at a median of 58 months. Eight patients, 4 in each group, were required to undergo surgery for removal of postchemotherapy residual masses. The results confirm that Cisplatin-based chemotherapy protocols are adequate to cure most patients with good-risk factors, and newer approaches are needed for patients at poor risk. © 1992 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text